TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study
- 1 January 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Acta Endocrinologica
- Vol. 158 (1), 69-75
- https://doi.org/10.1530/eje-07-0450
Abstract
Autoimmunity against the TSH receptor is a key pathogenic element in Graves' disease. The autoimmune aberration may be modified by therapy of the hyperthyroidism. To compare the effects of the common types of therapy for Graves' hyperthyroidism on TSH-receptor autoimmunity. Patients with newly diagnosed Graves' hyperthyroidism aged 20-55 years were randomized to medical therapy, thyroid surgery, or radioiodine therapy (radioiodine was only given to patients > or = 35 years of age). L-thyroxine (L-T4) was added to therapy as appropriate to keep patients euthyroid. Anti-thyroid drugs were withdrawn after 18 months of therapy. TSH-receptor antibodies (TRAb) in serum were measured before and for 5 years after the initiation of therapy. Medical therapy (n=48) and surgery (n=47) were followed by a gradual decrease in TRAb in serum, with the disappearance of TRAb in 70-80% of the patients after 18 months. Radioiodine therapy (n=36) led to a 1-year long worsening of autoimmunity against the TSH receptor, and the number of patients entering remission of TSH-receptor autoimmunity with the disappearance of TRAb from serum during the following years was considerably lower than with the other types of therapy. The majority of patients with Graves' disease gradually enter remission of TSH-receptor autoimmunity during medical or after surgical therapy, with no difference between the types of therapy. Remission of TSH-receptor autoimmunity after radioiodine therapy is less common.Keywords
This publication has 30 references indexed in Scilit:
- Clinical results of anti‐inflammatory therapy in Graves’ ophthalmopathy and association with thyroidal autoantibodies*Clinical Endocrinology, 2004
- A New Assay for Thyrotropin Receptor AutoantibodiesThyroid®, 2004
- Comparison of Thyrotropin-Receptor Antibodies Measured by Four Commercially Available Methods with a Bioassay That Uses Fisher Rat Thyroid CellsClinical Chemistry, 2003
- Immunoglobulins of Untreated Graves' Patients with or without Thyrotropin Receptor Antibody (Determined by Porcine Thyrocytes) Universally Elicit Potent Thyroid Hormone-Releasing Activity in Cultured Human Thyroid FolliclesThyroid®, 1999
- Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study GroupJournal of Clinical Endocrinology & Metabolism, 1996
- A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti‐thyroid drugsClinical Endocrinology, 1995
- Long‐term effects of radioiodine on thyrotrophin receptor antibodies in Graves' diseaseClinical Endocrinology, 1995
- The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazoleJournal of Clinical Endocrinology & Metabolism, 1994
- Immunological findings and thyroid function of untreated Graves' disease patients with undetectable TSH‐binding inhibitor immunoglobulinClinical Endocrinology, 1994
- EFFECT OF RADIOIODINE ON STIMULATORY ACTIVITY OF GRAVES’IMMUNOGLOBULINSClinical Endocrinology, 1982